Clinical Edge Journal Scan

Gene mutation status impacts overall survival in acute myeloid leukemia

Publish date: March 31, 2021

Clinical Edge Journal Scan: AML April 2021 (5 of 10)


 

Key clinical point: Gene set variation analysis (GSVA) showed that the PI3K-Akt-mTOR pathway was positively related to FLT3-ITD mutation.

Major finding: In patients with acute myeloid leukemia, expression of RPS6KA1 and AP2M1 were predictors of chemoresistance and overall survival.

Study details: The data come from four genetic data sets: GSE6891, GSE10358, GSE15434, and GSE61804 of patients with acute myeloid leukemia.

Disclosures: The study was supported by the Young & Middle-aged Medical Key Talents Training Project of Wuhan. The researchers had no financial conflicts to disclose.

Source: Yu D-H et al. Front Cell Dev Biol. 2021 Feb 26. doi: 10.3389/fcell.2021.641629.

Recommended Reading

Using engineered T cells reduced acute, chronic GVHD
MDedge Hematology and Oncology
Maribavir seen as superior to other antivirals for CMV clearance post transplant
MDedge Hematology and Oncology
Don’t delay: Cancer patients need both doses of COVID vaccine
MDedge Hematology and Oncology
Omidubicel improves on umbilical cord blood transplants
MDedge Hematology and Oncology
Risk factors predict graft failure in pediatric acute leukemia patients
MDedge Hematology and Oncology
Rural AML patients fare as well as urban patients for survival and treatment
MDedge Hematology and Oncology
Early tumor cell response predicts AML treatment success
MDedge Hematology and Oncology
Green tea extract promotes immune system function in older AML patients
MDedge Hematology and Oncology
Venetoclax succeeds for AML remission in untreated older patients
MDedge Hematology and Oncology
Glasdegib and venetoclax show similar success for AML
MDedge Hematology and Oncology

Clinical Edge Journal Scan: AML April 2021 (5 of 10)